ClinicalTrials.gg
CompletedNCT04972227Updated Aug 13, 2024

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

A Phase 1 interventional study of CY6463 and Placebo in Schizophrenia, sponsored by Tisento Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Tisento Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
805th of 1,319
48 · median 66
Started
2021
with 52 others
Phase 1
196 of 1,465
10 open now
Registered
1,224th of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 805th largest by enrollment of the 1,319 interventional ones that give a count, is one of 53 that started in 2021, is one of 196 in phase 1, and was the 1,224th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Cognitive Impairment Associated with Schizophrenia
  • CIAS
  • CY6463
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provides written to participate in this study
  2. is between 18 to 40 kg/m2
  3. Fluent English speaker
  4. Diagnosed with schizophrenia at least 1 year ago
  5. Psychiatrically stable schizophrenia with no more than moderate symptomatology
  6. On a stable atypical antipsychotic regimen
  7. Agrees to use effective throughout the study and for at least 3 months afterward
  8. Agrees to avoid using tobacco/nicotine and caffeine for several hours at a time
  9. Agrees to not participate in another study of a drug or device while in this study

Exclusion criteria

EXCLUSION CRITERIA:

  1. Was in another study of a drug in the past 2 months
  2. Fails a drug/alcohol screen, including amphetamines, barbiturates, cocaine, marijuana, methadone, methamphetamine, 3,4 methylenedioxymethamphetamine (MDMA), phencyclidine, or nonprescribed benzodiazepines or opiates
  3. Has had a recent heavy smoking habit (>40 cigarettes/2 packs/day) or recently had nicotine replacement therapy
  4. Has significant heart disease
  5. Has hemophilia or any other bleeding/ dysfunction condition
  6. Has hepatitis or

Additional inclusion and exclusion criteria apply, per protocol.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    CY6463

    CY6463 once-daily (QD) for 14 days

    Drug: CY6463

  • Placebo comparator
    Placebo

    placebo QD for 14 days

    Drug: Placebo

Interventions

  • DrugCY6463

    oral tablets

    Also known as: IW-6463, Zagociguat

  • DrugPlacebo

    oral tablets

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to study drug discontinuation

    Time frame: 28 (±4) days

Secondary outcomes

  1. Plasma concentrations of CY6463

    Time frame: up to Day 15

  2. Pharmacokinetic (PK) parameter: area under the concentration-time curve from time zero (predose) to 24 hours postdose (AUC0-24)

    Time frame: up to Day 15

  3. PK parameter: area under the concentration-time curve during a dosing interval (AUCtau)

    Time frame: up to Day 15

  4. PK parameter: average concentration during a dosing interval (Cavg)

    Time frame: up to Day 15

  5. PK parameter: maximum observed concentration (Cmax)

    Time frame: up to Day 15

  6. PK parameter: time to maximum observed concentration (Tmax)

    Time frame: up to Day 15

  7. PK parameter: minimum observed concentration (Cmin)

    Time frame: up to Day 15

  8. PK parameter: apparent systemic clearance (CL/F)

    Time frame: up to Day 15

  9. PK parameter: accumulation ratio based on a comparison of AUC values after single and multiple dosing (RAUC)

    Time frame: up to Day 15

  10. PK parameter: accumulation ratio based on a comparison of Cmax values after single and multiple dosing (RCmax)

    Time frame: up to Day 15

07

Study locations

2 sites
  • Collaborative Neuroscience Network
    Long Beach, California 90806, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Apr 2022, 7 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2021
First posted
Jul 22, 2021
StartActual
Sep 10, 2021
Primary completionActual
Apr 18, 2022
CompletionActual
Apr 18, 2022
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04972227
Lead sponsor
Tisento Therapeutics
Responsible party
Sponsor
First posted
Jul 22, 2021
Start date
Sep 10, 2021
Primary completion
Apr 18, 2022
Completion
Apr 18, 2022
Last update
Aug 13, 2024

Study contacts

Jennifer Chickering
study director · Cyclerion Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zagociguat

Start the discussion